JP2013515486A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515486A5
JP2013515486A5 JP2012546229A JP2012546229A JP2013515486A5 JP 2013515486 A5 JP2013515486 A5 JP 2013515486A5 JP 2012546229 A JP2012546229 A JP 2012546229A JP 2012546229 A JP2012546229 A JP 2012546229A JP 2013515486 A5 JP2013515486 A5 JP 2013515486A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515486A (ja
JP6000855B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/061987 external-priority patent/WO2011079257A2/en
Publication of JP2013515486A publication Critical patent/JP2013515486A/ja
Publication of JP2013515486A5 publication Critical patent/JP2013515486A5/ja
Application granted granted Critical
Publication of JP6000855B2 publication Critical patent/JP6000855B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546229A 2009-12-24 2010-12-23 ヒトアンギオポエチン様タンパク質４に対するヒト抗体 Expired - Fee Related JP6000855B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US29009209P 2009-12-24 2009-12-24
US61/290,092 2009-12-24
US30635910P 2010-02-19 2010-02-19
US61/306,359 2010-02-19
US32831610P 2010-04-27 2010-04-27
US61/328,316 2010-04-27
US34927310P 2010-05-28 2010-05-28
US61/349,273 2010-05-28
US35612610P 2010-06-18 2010-06-18
US61/356,126 2010-06-18
PCT/US2010/061987 WO2011079257A2 (en) 2009-12-24 2010-12-23 Human antibodies to human angiopoietin-like protein 4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015096446A Division JP2015145424A (ja) 2009-12-24 2015-05-11 ヒトアンギオポエチン様タンパク質４に対するヒト抗体

Publications (3)

Publication Number Publication Date
JP2013515486A JP2013515486A (ja) 2013-05-09
JP2013515486A5 true JP2013515486A5 (enExample) 2014-02-06
JP6000855B2 JP6000855B2 (ja) 2016-10-05

Family

ID=43629324

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012546229A Expired - Fee Related JP6000855B2 (ja) 2009-12-24 2010-12-23 ヒトアンギオポエチン様タンパク質４に対するヒト抗体
JP2015096446A Pending JP2015145424A (ja) 2009-12-24 2015-05-11 ヒトアンギオポエチン様タンパク質４に対するヒト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015096446A Pending JP2015145424A (ja) 2009-12-24 2015-05-11 ヒトアンギオポエチン様タンパク質４に対するヒト抗体

Country Status (30)

Country Link
US (2) US8354103B2 (enExample)
EP (1) EP2516466B1 (enExample)
JP (2) JP6000855B2 (enExample)
KR (1) KR101842570B1 (enExample)
CN (1) CN102741284A (enExample)
AR (1) AR079708A1 (enExample)
AU (1) AU2010336369C1 (enExample)
BR (1) BR112012017765A2 (enExample)
CA (1) CA2785158C (enExample)
CY (1) CY1118898T1 (enExample)
DK (1) DK2516466T3 (enExample)
ES (1) ES2628135T3 (enExample)
HR (1) HRP20170524T1 (enExample)
HU (1) HUE034722T2 (enExample)
IL (1) IL220402A (enExample)
JO (1) JO3274B1 (enExample)
LT (1) LT2516466T (enExample)
MX (1) MX337082B (enExample)
NZ (1) NZ600768A (enExample)
PL (1) PL2516466T3 (enExample)
PT (1) PT2516466T (enExample)
RS (1) RS56009B1 (enExample)
RU (1) RU2580045C2 (enExample)
SG (1) SG181784A1 (enExample)
SI (1) SI2516466T1 (enExample)
SM (1) SMT201700280T1 (enExample)
TW (1) TWI488643B (enExample)
UY (1) UY33144A (enExample)
WO (1) WO2011079257A2 (enExample)
ZA (1) ZA201204507B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
BR112013018740A2 (pt) 2011-01-28 2019-01-08 Sanofi Sa anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
BR112014006390A2 (pt) * 2011-09-19 2017-03-28 Kymab Ltd anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
US20150071941A1 (en) * 2012-04-13 2015-03-12 The Johns Hopkins University Treatment of ischemic retinopathies
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
US20150210753A1 (en) 2012-07-26 2015-07-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
TWI596115B (zh) 2012-08-13 2017-08-21 再生元醫藥公司 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
WO2014200898A2 (en) * 2013-06-10 2014-12-18 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
KR101538787B1 (ko) * 2013-06-27 2015-07-22 인하대학교 산학협력단 췌장염 진단용 바이오 마커 조성물
AU2015204840B2 (en) * 2014-01-07 2020-01-30 Bioatla, Llc Proteins targeting orthologs
WO2016020882A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
PT3177642T (pt) * 2014-08-07 2022-02-14 Novartis Ag Anticorpos semelhantes a angiopoietina 4 e métodos de uso
US9556225B2 (en) * 2014-10-15 2017-01-31 Uniao Quimica Farmaceutica Nacional S/A Peptide stimulator of cell survival and proliferation
US20180125816A1 (en) 2015-05-11 2018-05-10 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
EA201991203A1 (ru) 2016-11-17 2019-10-31 Способы лечения ожирения антителами к angptl8
US11046764B2 (en) 2017-01-03 2021-06-29 Trellis Bioscience, Llc Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
EP3938405A4 (en) * 2019-03-20 2022-12-28 Javelin Oncology, Inc. ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS THEREOF
CN113795510A (zh) 2019-08-29 2021-12-14 荣昌生物制药(烟台)股份有限公司 抗pd-l1抗体及其应用
JP2023514000A (ja) * 2019-12-09 2023-04-05 エンピリコ インク． アンジオポエチン様４（ａｎｇｐｔｌ４）関連疾患の処置のためのオリゴヌクレオチド
EP3872091B1 (en) 2020-02-26 2023-06-14 VIR Biotechnology, Inc. Antibodies against sars-cov-2
WO2022006555A2 (en) * 2020-07-02 2022-01-06 Gigagen, Inc. BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
JP2023533253A (ja) * 2020-07-02 2023-08-02 マブリティクス， インコーポレイテッド 細胞結合タンパク質および使用の方法
WO2023239307A1 (en) * 2022-06-10 2023-12-14 Nanyang Technological University Methods of treating liver fibrosis, inflammation or associated diseases using an angptl4 antagonist
JP2025527263A (ja) * 2022-08-02 2025-08-20 ノナ・バイオサイエンシズ（スーチョウ）カンパニー，リミテッド Ｍｓｌｎ抗体－薬物コンジュゲート
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
WO2006068953A2 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US7655762B2 (en) 2005-01-07 2010-02-02 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against ANGPTL4
JP5489465B2 (ja) 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
AU2007227251A1 (en) * 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Similar Documents

Publication Publication Date Title
JP2013515486A5 (enExample)
RU2012131547A (ru) Антитела человека против ангиопоэтин-подобного белка 4 человека
US11542325B2 (en) Anti-activin A antibodies and uses thereof
RU2013155906A (ru) Антитела анти-angptl3 и их применение
US10561653B2 (en) 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
US20160032014A1 (en) Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
RU2012156938A (ru) Антитела против gdf8 человека
RU2014147773A (ru) Человеческие антитела с высокой аффинностью к рецепторам il-4 человека
RU2011129316A (ru) Высокоаффинные человеческие антитела к pcsk9
JP2013542194A5 (enExample)
JP7292526B2 (ja) 操作された抗ｉｌ－２抗体
TW201412774A (zh) 能結合胸腺基質淋巴細胞生成素之抗原結合蛋白
JP2018510617A5 (enExample)
JP2016501892A5 (enExample)
JP2015503909A5 (enExample)
JP6949012B2 (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
RU2019139093A (ru) Фармацевтическая композиция на основе антитела к pd-l1 и ее применение
RU2016122340A (ru) Il-17a-связующий агент и способы его применения
JP2019162119A5 (enExample)
EP2766394A1 (en) Treatment for rheumatoid arthritis
CN111094339A (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
WO2014072741A1 (en) Humanised antibody and method of production thereof
CA2824313A1 (en) Tlr3 binding agents
WO2018080914A1 (en) Anti-rankl antibodies and uses thereof
WO2021063331A1 (zh) EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途